Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES Academic Article uri icon

Overview

MeSH Major

  • Antiviral Agents
  • Hepatitis C, Chronic
  • Kidney Diseases
  • Liver Cirrhosis

abstract

  • The incidence of hepatic decompensation in persons treated with PrOD, up to 12 weeks after completion of treatment, was comparable to those treated with sofosbuvir/ledipasvir regimen, and was lower than among those treated with a sofosbuvir/simeprevir regimen. Such risk was predominantly observed in those with pre-treatment cirrhosis.

publication date

  • January 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1111/apt.13837

PubMed ID

  • 27813162

Additional Document Info

start page

  • 150

end page

  • 159

volume

  • 45

number

  • 1